fda warning letter compounded semaglutide september 2025 GLP-1 Compounding: When Innovation May Mean Liability Maybe i’m not against compounding

Potential mechanisms Mol Metab 46:101139 Stern JH, Smith GI, Chen S, Unger RH, Klein S, Scherer PE (2019) Obesity dysregulates fasting-induced changes in glucagon secretion

The exact mechanism behind this finding remains unproven, as the studies are still in abstract form, so knowing the reasoning behind this is still difficult

GLP-1 receptor agonists also suppress glucagon secretion from pancreatic alpha cells, slow gastric emptying, and promote satiety through central nervous system pathways

1 Like Davin8r November 12, 2023, 7:10pm #12 tongMD: If you look at the actual trials for approval on weight loss - it is always paired with specific diet/exercise interventions

This combined activity reduces food intake, improves insulin sensitivity, and increases metabolic rate

They tend to go away with time as your body gets used to the medication